The subsidiary of Changchun High-Tech Industry (000661.SZ) Injection GenSci143 for domestic production of drugs has obtained approval for clinical trial registration application.

Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (hereinafter referred to as "JinSai Pharmaceutical"), has received the approved and issued "Clinical Trial Authorization Notice" from the National Medical Products Administration to conduct clinical trials of GenSci143 in patients with advanced solid tumors. GenSci143 is a type 1 biopharmaceutical drug independently developed by JinSai Pharmaceutical, intended for the treatment of various advanced solid tumors such as prostate cancer and lung cancer. As a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA, GenSci143 has dual potential therapeutic effects in targeted chemotherapy and tumor immunotherapy, capable of overcoming tumor heterogeneity and drug resistance caused by decreased expression of a single target, thereby covering more patients and producing more durable anti-tumor effects.